



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-22-2021	Data/Ora Ricezione 26 Aprile 2021 16:23:47	MTA - Star
---	---	------------

Societa' : Pharmanutra S.p.A.  
Identificativo : 145867  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : 1.1; REGEM  
Data/Ora Ricezione : 26 Aprile 2021 16:23:47  
Data/Ora Inizio : 26 Aprile 2021 16:23:47  
Diffusione presunta  
Oggetto : PR - PHARMANUTRA Shareholders  
meeting 26 04 2021

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: ORDINARY SHAREHOLDERS' MEETING OF 26<sup>th</sup> APRIL 2021

- **Approves the financial statements for the year as at 31<sup>st</sup> December 2020 and a dividend of € 0.67 per share**
- **Approves the report on the remuneration policy and on fees paid**
- **Authorises the purchase and disposal of ordinary treasury stock, after revoking the authorisation granted by the Shareholders' Meeting of 27<sup>th</sup> April 2020**

Pisa, 26<sup>th</sup> April 2021 – The ordinary shareholders' meeting of [PharmaNutra S.p.A.](#) ("**PharmaNutra**" or the "**Company**") that met today in first call, approved the financial statements for the year closed as at 31<sup>st</sup> December 2020 within terms proposed by the Board of Directors and made public on 22<sup>nd</sup> March 2021 last.

The ordinary Shareholders' Meeting also resolved to distribute a unitary dividend of €0.67 for each share with rights. The coupon will be detached on 3<sup>rd</sup> May 2021, the payment record date pursuant to art. 83-terdecies of Legislative Decree 58/1998 (*record date*) on 4<sup>th</sup> May 2021 and payment on 5<sup>th</sup> May 2021.

The Shareholders' Meeting also acknowledged the financial statements of the PharmaNutra S.p.A. Group as at 31<sup>st</sup> December 2020 drafted in compliance with IFRS international accounting standards, providing the following main Group data:

- **€56.4 m net revenue (+5% compared to 2019)**
- **Consolidated RESTATED EBITDA €16.0 M (+22% compared to 2019)**
- **Consolidated RESTATED Net Income €11.6 M (+37% compared to 2019)**

A copy of the financial statements as at 31<sup>st</sup> December 2020 and of the consolidated financial statements of the PharmaNutra S.p.A. Group are available to the public in the registered office in Pisa, Via delle Lenze, no. 216/B and on the website of the Company [PharmaNutra.it](#), section [Investors Relations](#).

With a binding vote, the Shareholders' Meeting also approved section 1 of the Report on the remuneration policy and on fees paid, regarding the Company's Policy on the remuneration for administration body members and, with no prejudice to what is set forth in art. 2402 of the Italian Civil Code, the Board of Statutory Auditors. With a non-binding resolution, the Shareholders' Meeting also

approved Section II of the same Report, referred to fees paid during financial year 2020. A copy of the Report is available on the Company website, at the address [PharmaNutra.it](http://PharmaNutra.it), section [Governance / Shareholders' Meeting](#).

The Shareholders' Meeting also approved authorisation to purchase and dispose of ordinary treasury stock pursuant to arts. 2357 and 2357-ter of the Italian Civil Code, and art. 132 of Legislative Decree 58/1998, after revocation of the shareholders' meeting resolution of 27<sup>th</sup> April 2020 for the part not performed, in order for the Company to grasp the opportunity to make a beneficial investment in cases where the market price trend for PharmaNutra shares, also due to external factors, should not be able to express its true value. Hence, give the Company a useful, strategic investment opportunity for any purpose permitted by laws in force, including the use of shares as payment in extraordinary transactions, also the exchange of investments with other subjects, as part of transactions of interest to the Company, such as potential, further sector aggregations continually analysed and assessed by the Board of Directors. The Company also reserves the right to allocate shares purchased, based on the authorisation decided by the Shareholders' Meeting, to other purposes permitted by law in the interest of the Company, including their subsequent cancellation – within the terms and applying methods possibly decided by corporate bodies – and to dispose of them on or off exchange.

The authorisation has been granted for 18 months from the date of the Shareholders' Meeting decision for the purchase, even in several tranches, of a number of ordinary Company shares, with no nominal value indicated, for a counter value of maximum €3,000,000; at an amount that is no higher than the highest between the price of the last independent transaction and the price of the highest independent offer during negotiations where the purchase is made; without prejudice to the fact that the unitary amount may not be lower than the minimum of 20% and higher than the maximum of 10% compared to the reference price that the security recorded in the trading session of the day prior to each single transaction. The authorisation to dispose of ordinary treasury shares is granted with no time limits.

At this release date, the Company holds no ordinary treasury shares and its subsidiaries do not hold PharmaNutra shares.

The brief report on votes and the minutes of the Shareholders' Meeting will be made available to the public within terms and as established by laws in force.

*“Approving Financial Statements for 2020 with these results is very satisfying, and we are certain shareholders will share that satisfaction with us. The Group has proved to be extremely resilient in respect of markets, despite the succession of complicated conditions since the start of the Covid-19 emergency”, comments Roberto Lacorte, Vice President and CEO of PharmaNutra S.p.A. “Last year left us extremely solid bases*

on which to project the company's future. We expect to start growing at our customary rhythms again in 2021, following solid growth drivers like the continual strengthening of R&D, international expansion and consolidation of the sales network in Italy”.

The Manager in charge of drafting corporate accounts, Francesco Sarti, declares, pursuant to paragraph 2 of art. 154 *bis* of Legislative Decree 58/1998, that the account information in this press release corresponds to what is found in the accounts, books and records.

#### PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product. The effectiveness of its products is documented by considerable scientific proof, including 140 publications. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

#### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

#### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-22

Numero di Pagine: 5